SignalXSignalX

WGS GeneDx Holdings Corp.

Q3 2025 10-Q
Filed: Oct 28, 2025Period ending Sep 30, 2025
Health Care
Services-Health ServicesSEC EDGAR
GeneDx Holdings Corp. Overview

GeneDx Holdings Corp. (WGS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New regulatory risk: FDA final rule on lab-developed tests (LDTs) overturned March 31, 2025, creates ongoing uncertainty for LDT compliance
  • • Most material regulatory update: Potential enforcement of FDA oversight on LDTs could increase costs and reduce revenue, impacting financial condition
+3 more insights

Get deeper insights on GeneDx Holdings Corp.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.